4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Tvardi Therapeutics, Inc. (TVRD) operates in the Biotechnology industry and is headquartered in Sugar Land, United States with about 12 employees. Its market capitalization is roughly $36 million. In the fiscal year ended 2025-12-31, TVRD reported $0M in revenue and ($18M) in net income.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M |
| Operating Income (EBIT) | ($27M) | ($28M) | ($19M) | ($21M) |
| Net Income | ($18M) | ($29M) | ($17M) | ($20M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | — | — | — | $3M |
| Operating Income (EBIT) | ($7M) | ($8M) | ($6M) | ($9M) | ($4M) |
| Net Income | ($7M) | ($7M) | ($6M) | $4M | ($10M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Assets | $32M | $35M | $27M | $45M |
| Total Liabilities | $11M | $126M | $89M | $90M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive TVRD viewer.
About TickerBase · Data methodology & sources